Cited 14 times in
Chemoradiation With Paclitaxel and Carboplatin in High-Risk Cervical Cancer Patients After Radical Hysterectomy: A Korean Gynecologic Oncology Group Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김영태 | - |
dc.contributor.author | 김재훈 | - |
dc.date.accessioned | 2014-12-18T09:01:52Z | - |
dc.date.available | 2014-12-18T09:01:52Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0360-3016 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/87401 | - |
dc.description.abstract | PURPOSE: To evaluate the efficacy and toxicity of concurrent chemoradiation with paclitaxel and carboplatin in patients with high-risk cervical cancer. METHODS AND MATERIALS: Patients after radical hysterectomy for cervical cancer, with at least 1 high-risk characteristic, were administered paclitaxel 135 mg/m(2), carboplatin area under the curve = 5 every 3 weeks for 3 cycles concomitant with radiation therapy as adjuvant treatment. RESULTS: This prospective study enrolled 71 consecutive patients. Sixty-six patients (93%) completed the planned treatment. The majority of grade 3/4 neutropenia or nonhematologic toxicities were usually self-limited. Diarrhea grades 3/4 were observed in 4 patients (5.6%). One patient developed anaphylactic shock after infusion of paclitaxel. With a median follow-up of 57 months, recurrences occurred in 16 patients. Multivariable analysis indicated that common iliac lymph node involvement is an independent risk factor for disease recurrence (odds ratio 13.48; 95% confidence interval 2.93-62.03). In the intent-to-treat population (n=71), the estimated 5-year disease-free survival and overall survival rates were 77.3% and 80.3% respectively. In the per-protocol population (n=62), disease-free survival was 78.9% and overall survival was 83.9%. CONCLUSIONS: Concurrent chemoradiation with paclitaxel/carboplatin is well tolerated and seems to be effective for patients who undergo radical hysterectomy. Therefore, a prospective, randomized controlled study should be designed to evaluate efficacy of this approach for patients with high-risk cervical cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/mortality | - |
dc.subject.MESH | Adenocarcinoma/pathology | - |
dc.subject.MESH | Adenocarcinoma/therapy | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Analysis of Variance | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Area Under Curve | - |
dc.subject.MESH | Carboplatin/administration & dosage | - |
dc.subject.MESH | Carboplatin/adverse effects | - |
dc.subject.MESH | Carcinoma, Adenosquamous/mortality | - |
dc.subject.MESH | Carcinoma, Adenosquamous/pathology | - |
dc.subject.MESH | Carcinoma, Adenosquamous/therapy | - |
dc.subject.MESH | Carcinoma, Squamous Cell/mortality | - |
dc.subject.MESH | Carcinoma, Squamous Cell/pathology | - |
dc.subject.MESH | Carcinoma, Squamous Cell/therapy | - |
dc.subject.MESH | Chemoradiotherapy/adverse effects | - |
dc.subject.MESH | Chemoradiotherapy/methods* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hysterectomy | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.subject.MESH | Paclitaxel/administration & dosage | - |
dc.subject.MESH | Paclitaxel/adverse effects | - |
dc.subject.MESH | Postoperative Care/methods | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Radiotherapy Dosage | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Uterine Cervical Neoplasms/mortality | - |
dc.subject.MESH | Uterine Cervical Neoplasms/pathology | - |
dc.subject.MESH | Uterine Cervical Neoplasms/therapy* | - |
dc.title | Chemoradiation With Paclitaxel and Carboplatin in High-Risk Cervical Cancer Patients After Radical Hysterectomy: A Korean Gynecologic Oncology Group Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics & Gynecology (산부인과학) | - |
dc.contributor.googleauthor | Taek Sang Lee | - |
dc.contributor.googleauthor | Soon Beom Kang | - |
dc.contributor.googleauthor | Young Tak Kim | - |
dc.contributor.googleauthor | Byung Joo Park | - |
dc.contributor.googleauthor | Yong Man Kim | - |
dc.contributor.googleauthor | Jong Min Lee | - |
dc.contributor.googleauthor | Seok Mo Kim | - |
dc.contributor.googleauthor | Young Tae Kim | - |
dc.contributor.googleauthor | Jae Hoon Kim | - |
dc.contributor.googleauthor | Kyung Tai Kim | - |
dc.identifier.doi | 10.1016/j.ijrobp.2013.01.035 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00729 | - |
dc.contributor.localId | A00876 | - |
dc.relation.journalcode | J01157 | - |
dc.identifier.eissn | 1879-355X | - |
dc.identifier.pmid | 23642625 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0360301613001612 | - |
dc.subject.keyword | Adenocarcinoma/mortality | - |
dc.subject.keyword | Adenocarcinoma/pathology | - |
dc.subject.keyword | Adenocarcinoma/therapy | - |
dc.subject.keyword | Adult | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Analysis of Variance | - |
dc.subject.keyword | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.keyword | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.keyword | Area Under Curve | - |
dc.subject.keyword | Carboplatin/administration & dosage | - |
dc.subject.keyword | Carboplatin/adverse effects | - |
dc.subject.keyword | Carcinoma, Adenosquamous/mortality | - |
dc.subject.keyword | Carcinoma, Adenosquamous/pathology | - |
dc.subject.keyword | Carcinoma, Adenosquamous/therapy | - |
dc.subject.keyword | Carcinoma, Squamous Cell/mortality | - |
dc.subject.keyword | Carcinoma, Squamous Cell/pathology | - |
dc.subject.keyword | Carcinoma, Squamous Cell/therapy | - |
dc.subject.keyword | Chemoradiotherapy/adverse effects | - |
dc.subject.keyword | Chemoradiotherapy/methods* | - |
dc.subject.keyword | Disease-Free Survival | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Hysterectomy | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Neoplasm Recurrence, Local | - |
dc.subject.keyword | Paclitaxel/administration & dosage | - |
dc.subject.keyword | Paclitaxel/adverse effects | - |
dc.subject.keyword | Postoperative Care/methods | - |
dc.subject.keyword | Prospective Studies | - |
dc.subject.keyword | Radiotherapy Dosage | - |
dc.subject.keyword | Republic of Korea | - |
dc.subject.keyword | Survival Rate | - |
dc.subject.keyword | Uterine Cervical Neoplasms/mortality | - |
dc.subject.keyword | Uterine Cervical Neoplasms/pathology | - |
dc.subject.keyword | Uterine Cervical Neoplasms/therapy* | - |
dc.contributor.alternativeName | Kim, Young Tae | - |
dc.contributor.alternativeName | Kim, Jae Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Young Tae | - |
dc.contributor.affiliatedAuthor | Kim, Jae Hoon | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 86 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 304 | - |
dc.citation.endPage | 310 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.86(2) : 304-310, 2013 | - |
dc.identifier.rimsid | 33033 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.